BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 2860942)

  • 1. Which component of sulphasalazine is active in rheumatoid arthritis?
    Pullar T; Hunter JA; Capell HA
    Br Med J (Clin Res Ed); 1985 May; 290(6481):1535-8. PubMed ID: 2860942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
    Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
    Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis.
    Neumann VC; Taggart AJ; Le Gallez P; Astbury C; Hill J; Bird HA
    J Rheumatol; 1986 Apr; 13(2):285-7. PubMed ID: 2873245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of 5-aminosalicylic acid as a constituent of sulfasalazine in the treatment of chronic polyarthritis].
    Wörth WD; Müller W
    Z Rheumatol; 1986; 45(2):79-82. PubMed ID: 2873695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.
    van Hees PA; Bakker JH; van Tongeren JH
    Gut; 1980 Jul; 21(7):632-5. PubMed ID: 6107263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents (sulphapyridine and 5-aminosalicylic acid) in rats.
    Garg GP; Cho CH; Ogle CW
    Pharmacology; 1990; 40(6):318-24. PubMed ID: 1978355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active therapeutic moiety of sulphasalazine.
    van Hees PA; van Tongeren JH; Bakker JH; van Lier HJ
    Lancet; 1978 Feb; 1(8058):277. PubMed ID: 74700
    [No Abstract]   [Full Text] [Related]  

  • 8. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
    Bird HA
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
    Rao SS; Cann PA; Holdsworth CD
    Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.
    Pullar T; Hunter JA; Capell HA
    Br J Rheumatol; 1985 Aug; 24(3):269-76. PubMed ID: 2861876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which component of sulphasalazine is active in rheumatoid arthritis?
    Situnayake RD; McConkey B
    Br Med J (Clin Res Ed); 1985 Jul; 291(6488):138. PubMed ID: 2861878
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo.
    Sheldon P; Pell P
    Adv Exp Med Biol; 1995; 371B():905-8. PubMed ID: 7502923
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of sulphasalazine on neutrophil superoxide generation in rheumatoid arthritis.
    Bradley SM; le Gallez P; Throughton PR; Gooi HC; Astbury C; Bird HA
    Br J Rheumatol; 1997 May; 36(5):530-4. PubMed ID: 9189053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and synovial fluid concentrations of sulphasalazine and two of its metabolites in rheumatoid arthritis.
    Farr M; Brodrick A; Bacon PA
    Rheumatol Int; 1985; 5(6):247-51. PubMed ID: 2906452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
    Astbury C; Taggart AJ; Juby L; Zebouni L; Bird HA
    Ann Rheum Dis; 1990 Aug; 49(8):587-90. PubMed ID: 1975737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.
    Pullar T; Hunter JA; Capell HA
    Br Med J (Clin Res Ed); 1983 Oct; 287(6399):1102-4. PubMed ID: 6138117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.